THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.33] ID: TIP-MED-000265 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Pralidoxime Chloride / Iodide (2-PAM Cholinesterase Reactivator)

Active Ingredient / Scientific Identity: Pralidoxime Chloride / Iodide • Class: Cholinesterase Reactivator Oxime Antidote (Organophosphate Antidote)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Pralidoxime Chloride / Iodide (2-PAM Cholinesterase Reactivator) ([12.33] | ID: TIP-MED-000265) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/12-33-pralidoxime-chloride-iodide-2-pam-cholinesterase-reactivator/
Generic / Entity NamePralidoxime Chloride / Iodide (2-PAM Cholinesterase Reactivator) ([12.33])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCholinesterase Reactivator Oxime Antidote (Organophosphate Antidote)
Available Dosage FormsInjection (Pralidoxime Chloride or Iodide): 500 mg/20 mL vial, 1 g vial (lyophilised powder or solution).
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted 80-90% unchanged by kidneys within 6 hours; reduce maintenance infusion rate proportionally in renal impairme
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Pralidoxime Chloride / Iodide (2-PAM Cholinesterase Reactivator) (TIP-MED-000265, Reference Code [12.33]) is classified under Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Cholinesterase Reactivator Oxime Antidote (Organophosphate Antidote). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.33], p. 171): Aldopam, Pam-Inj, Neopam — Strengths & Dosage Forms: Injection (Pralidoxime Chloride or Iodide): 500 mg/20 mL vial, 1 g vial (lyophilised powder or solution).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.33], p. 171): Aldopam, Pam-Inj, Neopam — Strengths & Dosage Forms: Injection (Pralidoxime Chloride or Iodide): 500 mg/20 mL vial, 1 g vial (lyophilised powder or solution).
Dosage Forms & Available Strengths:
Injection (Pralidoxime Chloride or Iodide): 500 mg/20 mL vial, 1 g vial (lyophilised powder or solution).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Nucleophilic oxime group cleaves the phosphorylated bond on acetylcholinesterase BEFORE irreversible dealkylation ('ageing') occurs -> regenerates active acetylcholinesterase at nicotinic neuromuscular junctions and muscarinic sites.

4. Therapeutic Indications & Evidence-Supported Uses

  • Adjunct to Atropine in moderate-to-severe Organophosphate (OP) insecticide or nerve-agent poisoning to reverse nicotinic neuromuscular weakness, fasciculations, and respiratory muscle paralysis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: WHO High-Dose Regimen (after initial Atropinisation): Loading dose 30 mg/kg (typically 1–2 g) diluted in 100 mL 0.9% NaCl infused IV over 20–30 minutes, followed by continuous IV infusion of 8–10 mg/kg/hour (typically 500 mg/hour) until atropine has been stopped for 12–24 hours and patient is extubated. • Paediatric: Loading dose 25–50 mg/kg (max 2 g) IV over 30 min, followed by continuous infusion of 10–20 mg/kg/hour.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Excreted 80-90% unchanged by kidneys within 6 hours; reduce maintenance infusion rate proportionally in renal impairment. • Hepatic: No adjustment required.
Elimination & Renal Adjustment:
Renal: Excreted 80-90% unchanged by kidneys within 6 hours; reduce maintenance infusion rate proportionally in renal impairment. • Hepatic: No adjustment required.
Hepatic Impairment Considerations:
Renal: Excreted 80-90% unchanged by kidneys within 6 hours; reduce maintenance infusion rate proportionally in renal impairment. • Hepatic: No adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: CARBAMATE INSECTICIDE POISONING (e.g., Carbaryl/Sevin, Propoxur/Baygon, Carbofuran/Furadan) — carbamate-cholinesterase binding reverses spontaneously and Pralidoxime may worsen carbaryl toxicity (exception: mixed or unknown severe cholinergic poisoning where OP cannot be excluded). • Precautions: Rapid IV bolus (>200 mg/min) causes laryngospasm, muscle rigidity, tachycardia, hypertension, and transient neuromuscular blockade—MUST ALWAYS be infused slowly over 20–30 minutes! Administer as early as possible (dimethyl OPs like Dimethoate/Malathion 'age' within hours, whereas diethyl OPs like Chlorpyrifos/Parathion age over 36–48 hours).

Key Clinical Precautions: Renal: Excreted 80-90% unchanged by kidneys within 6 hours; reduce maintenance infusion rate proportionally in renal impairment. • Hepatic: No adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Blurred vision, diplopia, dizziness, nausea, transient systolic/diastolic hypertension.
  • Laryngospasm, muscular rigidity, and cardiac arrest if injected too rapidly.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Synergistic with Atropine (always give Atropine first; as Pralidoxime reactivates cholinesterase, watch for signs of atropine toxicity and adjust atropine rate); avoid Succinylcholine and Aminophylline/Morphine in OP poisoning

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Emergency hospital antidote; family should bring the pesticide container/label to the emergency department so clinicians can identify whether it is an Organophosphate (dimethyl vs diethyl) or Carbamate.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Injection (Pralidoxime Chloride or Iodide): 500 mg/20 mL vial, 1 g vial (lyophilised powder or solution).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.33] (p. 171)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/12-33-pralidoxime-chloride-iodide-2-pam-cholinesterase-reactivator/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.